AbSci’s Positive Outlook: Strong Financial Position and Promising ABS-101 Developments Support Buy Rating

Analyst Gil Blum from Needham maintained a Buy rating on AbSci and decreased the price target to $8.00 from $9.00.

Gil Blum has given his Buy rating due to a combination of factors related to AbSci’s recent developments and financial positioning. The company’s initial results for ABS-101 in healthy volunteers are progressing as planned, with a positive outcome expected in the second half of 2025. Such results could validate AbSci’s platform and make ABS-101 attractive to large pharmaceutical companies.
Additionally, AbSci’s financial health is bolstered by a strong cash position, ending the second quarter of 2025 with $118 million and raising approximately $64 million through public markets in July. This financial strategy extends their cash runway into the first half of 2028. Furthermore, the anticipation of new pharmaceutical partnerships this year, excluding potential deals for ABS-101, contributes to the positive outlook and supports the Buy rating.